Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Robin....
Its a tough time for pharma/biotech or many small comps. And SAR need to get into that 1b zone to produce data from humans. That's a common sense reading. Unless someone knows a lot about these kinds of compounds and see value here, at this stage. I'm not a pharma/bio PHD so I can't comment on that.
I'm pretty sure the maths for the shorters is a sub 10p stock. But I always like the possibility of a left-field play - and the maths for anyone trying to play guardian angel with seven figures plus - I imagine that maths is changing on a daily basis.
We shall see. Certainly post-placing there will be a flood of buys - but thats cold comfort, I imagine, if you are already underwater.
Thankfully nobody listened to that guru (M0ron) and held their nerve. Gla x
Carter I never sold one share thought gone past this stage price held up quite well B4 we had those two disastrous events, ie RF consolidation & oh peel hunt, let's hope prey 🙏 this gets sorted
Rgds
Ray
Can’t believe you never sold gunner
You got me on that one. I have no idea.
I see no reason why there should be a lack of information on this as Sareum has 27.5% financial interest.
Acrivon raised 100 million dollars for discontinued Prexasertib as related to myocarditis.
737 there was not an associated problem.
All very quiet on this front.
Not of benefit to Sareum if they were pinning their hopes on much larger upfront payment.
I would expect update or confirmation here in first week of April. Around 3 months from start to finish to agreement finalisation.
Regards
SAD and where is the money from the 737 deal so far ?? We had nothing to do with it we have had our pants pulled down again nearly 3 months in and not even signing on fee as the deal has not been done the only ones getting done is us
GLA
Hood,
A licencing deal sonny does not involve dilution.
Let me carefully put to you.
A licensing deal consists of an upfront payment, followed by milestone payments.
Please explain where the dilution comes in.
Hood,
I will keep it short especially for you.
The compound CCT245737 was developed by Sareum in partnership with the ICR/CRT
Regards
Hood, you are getting desperate sonny!
More utter garbage from you.
It’s a heavily discounted placing or a one in a million shot of some kind of non-dilutive funding like a licensing deal. The Holy Grail for small cap pharmas that never actually happens in real-life, especially to companies who don’t have any efficacy data.
Take a look at CCT245737 compound that was licenced a while ago.that was in phase1 clinical trial being of safety profile only. No clinical efficacy results as phase 1.
Upfront payment was smallish but total including milestone payments was circa 300 million.
So they do happen and not once in a million probability
Regards
Are you some kind of Knuckle dragger or just stupid, what I or anyone else does on here is none of you business, jog on you bore.
I wonder about the bucket shops. Yes that might happen. But it might not. They might have someone they can touch on. They managed to get some interest in 737 - so there are channels between SAR and £ (or in the case it was $?). See what happens. I do feel they are a bit cr*p - as many have said, why on earth didn't they raise when the sp was high - it makes sense to raise when you DON"T need the money - and I don't think enough AIM companies do that. Anyway lets see what happens next.
Dead right Parrot .. no one likes a “know all” .. let alone God
None of your business is it Hood where people invest their money, the Good Samaritan that you are. Your like some irritating mosquito.
I still think the Sareum board will find the money we need to progress, whether the terms are good, we will have to wait and see and the data is due soon on the trials as well. Pinkies crossed.
Just as my beloved ManU somehow contrived to beat Liverpool, the much better team today, against all the odds then hopefully SAR can overcome the odds currently stacked against them and come though this very difficult time and achieve their goals!!
Good afternoon Carter19.
The Hood asks questions and makes out he is clever, cunning yes, but not clever.
ADVN share chat very amusing.
Poor Robin is being bullied.
Stays in a box room at his mums or similar.
That bullying talk?
Very similar overtones to that circle of life deviant that was scaremongering about nitrosamines a while back. It don't post here anymore.
I have posted 5 times at night so must be worried about my investment in Sareum.
Jeez you have to laugh.
I post at night when l get called onto work.
At times the work does not go ahead so l am stuck in my off site cabin with a pager.
Trust all is well with you.
Regards
Regards
Hood
You really ate an odd ball.
Note carefully below the reply l received from Sareum
Read and try to understand
'Thank you for your email and interest in supporting Sareum, which is much appreciated.
As noted in our RNS of March 12, we are currently assessing funding sources. Should we pursue an equity fundraise, as we have done before we would anticipate giving existing shareholders the opportunity to participate. As we have done in the past, we would expect this would be through one of the retail platforms such as Wrap or Bookbuild. If this is the case, then full details will be announced to the market, and we will ensure that in addition we send you a copy of that announcement.'
With best regards, Sareum IR'
'We are assessing funding sources,'
'Should we pursue an equity fundraise'
From what is written above Sareum have more than one option of how to raise funds.
First part of phase 1 ie phase 1 completed with expected top line results.
That from dualified people a bit further up the knowledge tree than you are likely to ever reach.
You know nothing of the company and nothing about the biotech business.
You post nothing of substance just the same old childish drivel.
I remember the Puma posting.
Sareum will have the option to onlicence on phase1a data alone or raise funds to progress to phase1b
At phase 1a value less with smaller upfront payment. Phase 1b higher value larger upfront payment.
Most likely out come will be an on license during phase 1b trials in my honest opinion.
Sareum will overcome this problem irrespective of what ever you post here.
Your only interest is the SP falling.
You spout absolute unsubstantiated rubbish to push your agenda.
Have a good day and your time frame with regards of your short working are rapidly coming to an end.
S
Know the feeling franky99
Was 3,200% up on GGP by late 2019 having been invested since 2014, but have seen over £650k in profit evaporate ever since! 😢
Post below relating to Aurora +FLT3
https://pubmed.ncbi.nlm.nih.gov/34446858/
Although it does not mention Sareum l am pretty sure it is the Sareum compound.
Why would l think that?
CCT245738. First numbers relate to heterocyclic rings and molecule structure.
There was no advancement in this as halted by solubility issues for sufficient amounts if the compound to be taken intravenously.
An option would be via the oral route.
Unfortunately to continue development of SDC-1801 funds were diverted away from progress of
Aurora FLT3.
Nothing of any significance here regarding future funding, it is shelved until we are notified otherwise.
Https://www.factmr.com/report/immune-checkpoint-inhibitor-market#:~:text=Immune%20Checkpoint%20Inhibitor%20Market%20Outlook,14.7%25%20from%202024%20to%202034.
Https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9671062/#:~:text=LATTICE%2DUC%20was%20a%20double,more%20conventional%20or%20biologic%20therapies.
Hood,
'It’s probably not enough, realistically. You really want it to get you to the end of Ph1b. How long is that going to take? 2-3 years at least at the pace these guys typically operate, I’d say.'
What a load of tosh you post here.
Plan is to complete phase1b at end of 2024. This is notified to us numerous times via RNS'S. These statements have far more credibility than any of your ill conceived opinions.
One reason that Sareum would have used this facility is to prove that they have the ability to access finance to fund the stage1 trial.
This is a requirement of a CTA application. Without this access to funding the CTA application would never have been granted.
The first part ie 1a of the trial is basically complete and awaiting final detailed results that will enable from the point of view of satisfactory safety results to enter into phase1b.
With regards to finance our development of SDC1801 we are at later stage than end of preclinical. Top line results are expected as stated in Sareums RNS.
I would certainly take this having credibility over the complete and utter ill conceived drivel that you post here.
As for the 4 million required you make no sense.
You have stated when asked previously why a figure of 4 million and what will it be spent on and you ludicrously reply with directors salaries.
Sareum are working at seeking an alternative form of financing. This in reality should present no real problems on conclusion of 1a safety data along with biomarker data.
I am sure you understand the importance and knock on effect for this data not only for 1801 but also 1802.
If you cannot comprehend this or more likely refuse to acknowledge this fact then tt is evident that your knowledge and understanding of drug discovery, preclinical development, CTA application, phase1,2 and 3 stages of success with corresponding increase in value at each stage are at best very poor.
Regards.
Reality10, l would like to think that the BoD do visit this BB and dramatically change their attitude and communicate to us in such a way that they take on constructive criticism and address these issues, signalling to us that we are not investors that are bring taken for granted.
Surely that is in no way being unreasonable.
Regards
Again not difficult Robinhood. Set the bar low at 500k or enough to cover the completion of the first trials, with a cap at 3m. Then you’re not embarrassed if you come in at 800k or 1.2m if it’s over subscribed. That word alone would be positive and buy the company more time, could also throw in a future option for those that subscribe for the placing.
Ballater